hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06367647, orgStudyIdInfo id: zhujiangjy-20240229, briefTitle: Investigation on the Detection Rate of Pathogenic Viruses in Feces of Parenteral Infected Individuals, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-10-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Zhujiang Hospital, class: OTHER, descriptionModule briefSummary: This project is a cross-sectional study. Investigators plan to search and collect 1600 publicly published fecal metagenomic and metatranscriptome data through the Pubmed database, by summarizing and analyzing them to construct an enterovirus database. 200 apparently healthy individuals are planned to be enrolled. At the time of enrollment, fecal specimens of participants will be collected, and their demographic characteristics, disease and medication history, gastrointestinal status, dietary habits, lifestyle habits, and mental health information will be recorded. Another 200 specimens will be collected from patients with parenteral virus infection. The demographic characteristics and pathogen test results of the parenteral virus infected patients will be reviewed and recorded. By virus metagenomic sequencing on fecal specimens, investigators will identify which viruses can be detected in the intestinal tract of apparently healthy people, and to explore whether parenteral infection viruses can be detected in feces., conditionsModule conditions: Virus Infections, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 2000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: virus infection checklist, secondaryOutcomes measure: general information of apparently healthy individuals by questionnaire, secondaryOutcomes measure: Self-Rating Anxiety Scale SAS, secondaryOutcomes measure: Self-rating depression scale SDS, secondaryOutcomes measure: Pittsburgh sleep quality index PSQI, secondaryOutcomes measure: demographic characteristics case information of parenteral virus infected patients, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhujiang hospital of southern medical university, status: RECRUITING, city: Guangzhou, state: Guangdong, zip: 510280, country: China, contacts name: Yumei Liu, master, role: CONTACT, phone: +8618810795365, email: liuyumei1007@163.com, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06367634, orgStudyIdInfo id: TEO-TSUL-2301, briefTitle: TEOSYAL® PureSense ULTRA DEEP Versus Restylane® Lidocaine for the Correction of Moderate to Severe Nasolabial Folds in Chinese Adults, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-19, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Teoxane SA, class: INDUSTRY, descriptionModule briefSummary: This is a prospective, multi-center, randomized, controlled, subject- and evaluator-blinded clinical investigation to demonstrate non-inferiority of TEOSYAL® PureSense ULTRA DEEP compared to Restylane® Lidocaine for the correction of moderate to severe NLF in Chinese adults.Eligible subjects will be enrolled and randomized either to the treatment group or control group in a 1:1 ratio on Day 0. Each subject assigned to the treatment group will receive TEOSYAL® PureSense ULTRA DEEP in both NLFs, whereas subjects assigned to the control group will receive Restylane® Lidocaine.The treating investigator will administer the corresponding product in both NLFs of the subject on Day 0.All subjects will return to the site at 4, 12, 24, 36, and 52 weeks after the last treatment for effectiveness and safety assessment. All subjects will receive a safety phone call 7 days after the initial treatment at baseline, and after the touch-up treatment, if applicable., conditionsModule conditions: Nasolabial Folds, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Blinded-Live evaluator, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 390, type: ESTIMATED, armsInterventionsModule interventions name: injection in NLF, outcomesModule primaryOutcomes measure: WSRS grading, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Guangdong Second Provincial General Hospital, status: RECRUITING, city: Guangzhou, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06367621, orgStudyIdInfo id: CLS-015C, briefTitle: Retrospective Study of iStatis Syphilis Ab Test (POC), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-11-15, primaryCompletionDateStruct date: 2024-04-15, completionDateStruct date: 2024-04-15, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: bioLytical Laboratories, class: INDUSTRY, descriptionModule briefSummary: The purpose of this retrospective clinical trial is to establish the clinical performance of the iStatis Syphilis AbTest. The data will be used to demonstrate the product is safe and effective for its intended use. The data obtained will be used in the application for CE certification under In Vitro Diagnostic Medical Device Regulation (IVDR) and World Health Organization (WHO) prequalification., conditionsModule conditions: Syphilis, conditions: Syphilis Infection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1500, type: ACTUAL, armsInterventionsModule interventions name: iStatis Syphilis Antibody Test, outcomesModule primaryOutcomes measure: Sensitivity and specificity of the iStatis Syphilis Ab Test, eligibilityModule sex: ALL, minimumAge: 15 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Epicentre Health Research, city: Hillcrest, state: KwaZulu Natal, zip: 3650, country: South Africa, hasResults: False
protocolSection identificationModule nctId: NCT06367608, orgStudyIdInfo id: HP-00104695, briefTitle: MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD), acronym: FUS Dystonia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2027-06, completionDateStruct date: 2028-06, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University of Maryland, Baltimore, class: OTHER, collaborators name: Focused Ultrasound Foundation, collaborators name: InSightec, descriptionModule briefSummary: The purpose of this study is to assess the safety and effectiveness of MRI-guided focused ultrasound (MRgFUS) for treating task specific focal hand dystonias (TSFD). TSFD is a type of dystonia that affects hand movements during specific tasks such as writing, playing instruments or typing, often causing involuntarily movements or cramping., conditionsModule conditions: Task-Specific Focal Dystonia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DEVICE_FEASIBILITY, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: ExAblate Transcranial treatment, outcomesModule primaryOutcomes measure: Incidence of Treatment related adverse events, secondaryOutcomes measure: Change in dystonia intensity, secondaryOutcomes measure: Change in patient's perception of quality of life, secondaryOutcomes measure: Change in patient's perception of the effect of the procedure, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Maryland Medical Center, city: Baltimore, state: Maryland, zip: 21201, country: United States, contacts name: Kaitlyn Henry, MS, role: CONTACT, phone: 410-328-0939, email: khenry@som.umaryland.edu, contacts name: Rayne Noyes, BS, role: CONTACT, email: anoyes@som.umaryland.edu, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06367595, orgStudyIdInfo id: Intrathecal MgSO4, briefTitle: Effect of Intrathecal Magnesium Sulfate Versus Intravenous Magnesium Sulfate on Postoperative Pain After Abdominal Hysterectomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-10, completionDateStruct date: 2026-11, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The present study aims to compare the effect of adding IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine in total abdominal hysterectomy regarding the duration of postoperative analgesia, hemodynamic stability, and complications., conditionsModule conditions: Abdominal Hysterectomy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Magnesium sulfate, outcomesModule primaryOutcomes measure: effect on postoperative pain after abdominal hysterectomy using visual analog score, secondaryOutcomes measure: sedation by Ramsay sedation scale, secondaryOutcomes measure: time of the first opioid request, secondaryOutcomes measure: Mean arterial blood pressures (MAP), secondaryOutcomes measure: Heart rate (HR), eligibilityModule sex: FEMALE, minimumAge: 40 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06367556, orgStudyIdInfo id: 4542, briefTitle: Emotion and Symptom-Focused Engagement (EASE) for Caregivers, acronym: EASE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2027-10-01, completionDateStruct date: 2028-10-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University Health Network, Toronto, class: OTHER, collaborators name: The Hospital for Sick Children, collaborators name: Canadian Institutes of Health Research (CIHR), descriptionModule briefSummary: The goal of this two-site phase III randomized controlled trial is to evaluate the effectiveness of a novel psychotherapeutic intervention called Emotion and Symptom-focused Engagement (EASE) in parents caring for a child or adolescent with cancer. The main question it aims to answer is:- Does EASE reduce traumatic stress symptom severity (primary outcome)?To do so, researchers will compare parents receiving EASE to usual care. Participants in both groups will complete questionnaires package at enrolment, and 4, 8, and 12 weeks, and 6 months after enrolment. They will also be invited to participate in optional qualitative interviews to better understand their experience., conditionsModule conditions: Trauma and Stressor Related Disorders, conditions: Pediatric Cancer, conditions: Caregiver Burden, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Quantitative outcome assessors and data analysts will be blinded to participant treatment group. Blinding is not possible for trial participants, intervention providers, or pediatric oncology teams, as assignment cannot be hidden from these individuals., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 306, type: ESTIMATED, armsInterventionsModule interventions name: EASE, outcomesModule primaryOutcomes measure: Posttraumatic Stress Disorder Checklist for DSM-5 [PCL-5], secondaryOutcomes measure: SF-36v2 Health Survey, secondaryOutcomes measure: Patient Health Questionnaire [PHQ-9], secondaryOutcomes measure: Caregiving Health Engagement Scale [CHE-s], secondaryOutcomes measure: Family Adaptability and Cohesion Evaluation Scales III [FACES-III], secondaryOutcomes measure: Clinical Evaluation Questionnaire [CEQ], secondaryOutcomes measure: Family Satisfaction with End-of-Life Care Tool, 10-item version [FAMCARE-10], otherOutcomes measure: Traditional Masculinity-Femininity Scale [TMF], otherOutcomes measure: Caregiver Reaction Assessment Scale [CRA], otherOutcomes measure: ENRICHD Social Support Instrument [ESSI], otherOutcomes measure: Experiences in Close Relationships Scale [ECR-16], otherOutcomes measure: Hope of Improvement subscale of the Therapy Expectation and Evaluation Scale [PATHEVH], eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06367543, orgStudyIdInfo id: AZ 117/22, briefTitle: Guideline-recommended Basic Parameter Adherence in Neurocritical Care Patients, acronym: NORMONICU, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-11-30, primaryCompletionDateStruct date: 2024-02-29, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: University of Giessen, class: OTHER, collaborators name: University of Leipzig, collaborators name: University of Wuerzburg, collaborators name: Technical University of Munich, collaborators name: Heidelberg University, collaborators name: University of Cologne, collaborators name: University of Mannheim, collaborators name: University Hospital, Essen, descriptionModule briefSummary: The aim of the planned study project is to assess the current situation regarding the treatment of patients with severe stroke at the neuro-critical care unit. Specifically, determination of whether the target parameters recommended in the guidelines for temperature, systolic blood pressure, mean arterial blood pressure, blood glucose, arterial oxygen partial pressure and arterial carbon dioxide partial pressure had to be maintained. From the planned data analysis, the need for the introduction of cerebrovascular bundles can be derived and planned., conditionsModule conditions: Stroke, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 474, type: ACTUAL, armsInterventionsModule interventions name: Time in therapeutic range of vital parameters, outcomesModule primaryOutcomes measure: Time in Therapy range, secondaryOutcomes measure: Acute measures, secondaryOutcomes measure: Invasive measures performed in the course of the Stay, secondaryOutcomes measure: Duration of ventilation, secondaryOutcomes measure: Deceased on Intensive Care., secondaryOutcomes measure: NIHSS (National Institutes of Health Stroke Scale)., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitätsklinikum Gießen, city: Gießen, state: Hessen, zip: 35392, country: Germany, geoPoint lat: 50.58727, lon: 8.67554, hasResults: False
protocolSection identificationModule nctId: NCT06367530, orgStudyIdInfo id: GS-TRIO-2024, briefTitle: Trilateral Retinoblastoma: Incidence and Outcomes, acronym: GS-TRIO, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2029-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Amsterdam UMC, location VUmc, class: OTHER, descriptionModule briefSummary: Patients with heritable retinoblastoma are at risk to develop an intracranial brain tumor, which is often fatal. The investigators intend to look at the incidence and survival of trilateral retinoblastoma (which is a brain tumor that can either be located in the pineal gland or elsewhere in the brain) in retinoblastoma patients globally. All retinoblastoma patients from participating centers will be included. The investigators hypothesize that the apparent incidence of trilateral retinoblastoma (especially the usually later diagnosed pineal trilateral retinoblastoma) in low-income countries will be lower because of low chances of surviving the ocular tumors at about 50% and also because of possible under-diagnosis. Therefore, as retinoblastoma care improves in low-income countries the incidence of (pineal) trilateral retinoblastoma might go up. Knowledge about incidence and survival can help improve health practices in parts of the world where this might be needed. Therefore this global study firstly aims 1) to evaluate survival after trilateral retinoblastoma and factors influencing survival and 2) to evaluate incidence of trilateral retinoblastoma by country income level. The study will run from 2024 through 2027., conditionsModule conditions: Trilateral Retinoblastoma, conditions: Retinoblastoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 4351, type: ESTIMATED, armsInterventionsModule interventions name: Incidence and survival of trilateral retinoblastoma and the differences globally, outcomesModule primaryOutcomes measure: Number of participants (retinoblastoma patients) that will be diagnosed with trilateral retinoblastoma (incidence), primaryOutcomes measure: Overall and event-free survival after being diagnosed with trilateral retinoblastoma, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Amsterdam UMC, status: RECRUITING, city: Amsterdam, state: Noord-Holland, zip: 1082HV, country: Netherlands, contacts name: Pim de Graaf, MD PhD, role: CONTACT, phone: 800-555-5555, email: p.degraaf@amsterdamumc.nl, geoPoint lat: 52.37403, lon: 4.88969, hasResults: False
protocolSection identificationModule nctId: NCT06367517, orgStudyIdInfo id: KB/114/2022, briefTitle: Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease), statusModule overallStatus: RECRUITING, startDateStruct date: 2021-05-20, primaryCompletionDateStruct date: 2025-05-20, completionDateStruct date: 2026-05-20, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Medical University of Warsaw, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease., conditionsModule conditions: Orbitopathy, Graves, conditions: Thyroid Eye Disease, conditions: Ophthalmopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Tocilizumab, outcomesModule primaryOutcomes measure: Disease improvement, primaryOutcomes measure: Improvement of quality of life, secondaryOutcomes measure: Disease inactivation, secondaryOutcomes measure: Proportion of patients achieving response in specific GO signs and symptoms, secondaryOutcomes measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, secondaryOutcomes measure: Decrease in concentration of thyrotropin receptor antibodies, secondaryOutcomes measure: Decrease in levels of proinflammatory cytokines, secondaryOutcomes measure: Number of the rehabilitative surgeries performed after immunosuppressive therapy, secondaryOutcomes measure: The rate of disease relapse, secondaryOutcomes measure: Decrease in proptosis by at least 2 mm assessed using magnetic resonance imaging (MRI), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Internal Medicine and Endocrinology, Medical University of Warsaw, status: RECRUITING, city: Warsaw, zip: 02-097, country: Poland, contacts name: Tomasz Bednarczuk, MD, PHD, role: CONTACT, email: tomasz.bednarczuk@wum.edu.pl, contacts name: Joanna Rymuza, MD, PHD, role: CONTACT, email: joanna.rymuza@wum.edu.pl, contacts name: Tomasz Bednarczuk, MD, PHD, role: PRINCIPAL_INVESTIGATOR, contacts name: Joanna Rymuza, MD, PHD, role: SUB_INVESTIGATOR, contacts name: Aleksander Kuś, MD, PHD, role: SUB_INVESTIGATOR, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06367478, orgStudyIdInfo id: SPEMG, briefTitle: Evaluation of Nerve Conduction Study, acronym: SPEMG, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2021-08-01, primaryCompletionDateStruct date: 2021-10-22, completionDateStruct date: 2024-10-22, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, class: OTHER, descriptionModule briefSummary: the investigators study different modality to obtain nerve evoked reponses. They use different parameters of acquisition and stimulation and they compare amplitude and latency of nerve conduction response, conditionsModule conditions: Nerve Condition, conditions: Health, Subjective, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 125, type: ACTUAL, outcomesModule primaryOutcomes measure: best amplitude of nerve conduction study, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan, city: Milan, zip: 20122, country: Italy, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False